Topline data expected to be available late 3Q2027
SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment of chronic hepatitis B virus (HBV) infection. Topline safety and efficacy data are expected to be available in late third quarter of 2027.
Part 1a completed enrollment of 131 HBeAg+ participants. This represents an over enrollment prior to the planned second interim analysis; therefore, the second interim analysis for sample size re-estimation will not be performed. Part 2a also completed enrollment of 114 HBeAg- participants.
"We are pleased to announce the completion of enrollment in our global Phase 2 B-SUPREME study of pevifoscorvir sodium," said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "Achieving full enrollment across study sites worldwide represents an important milestone for our organization and reflects the dedication of patients, investigators, healthcare professionals, and the Aligos team. This accomplishment advances our mission to develop transformative therapies for chronic hepatitis B virus infection and to reduce the burden of end-stage liver disease and hepatocellular carcinoma. We are deeply grateful to all study participants and their families for their commitment to this research. We look forward to reporting topline results in the late third quarter of next year and to continuing the advancement of pevifoscorvir sodium toward potential registration."
About B-SUPREME
The Phase 2 B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of pevifoscorvir sodium monotherapy compared with tenofovir disoproxil fumarate in approximately 250 untreated HBeAg+ and HBeAg- adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg+ part is HBV DNA